Exploiting metabolic vulnerabilities induced by dietary restriction as novel therapies for infant leukaemia

Prof Christina Halsey and Prof Katrin Ottersbach


Halsey Group
Ottersbach Group
Duration: 4 years from September 2022
Closing Date: 27th May 2022

About us

Applications are invited from outstanding candidates to join a Cancer Research UK funded PhD programme at the Institute of Cancer Sciences, University of Glasgow. These are funded by the Cancer Research UK Scotland Centre, a joint initiative between Edinburgh and Glasgow which brings together cancer scientists and clinicians from across the Universities of Edinburgh and Glasgow, delivering outstanding cancer research and improved patient care. The Cancer Research UK PhD programme is integrated into the research activities of the Centre with over 80 principal investigators contributing to this cross-disciplinary programme spanning from fundamental science to translational research. Research projects benefit from state-of-the art facilities for genomics, mass spectrometry, advanced microscopy, single cell technologies, and from advanced computational and informatics capabilities.

Project Description

Infant leukaemia is an aggressive malignancy with cure rates of less than 50%. Importantly, despite large international trials, there has been no improvement in survival over the last 2 decades. The major challenge is that while infant leukaemia is aggressive, necessitating high-intensity treatment strategies, babies are extremely vulnerable to toxicity from chemotherapy and stem cell transplantation. Novel non-toxic therapeutic approaches are desperately needed.

In this project you will follow-up on exciting observations that manipulating dietary intake of key nutrients, such as the amino-acid serine, sensitises leukaemia cells to drugs targeting key metabolic pathways such as nucleotide synthesis, lipid biosynthesis and cellular responses to energetic stress. One stumbling block in developing dietary interventions for cancer treatment to date has been the unpalatability of many nutrient restricted diets. However, Infant ALL is particularly suited to this approach because babies are usually fed via nasogastric tube or intravenously during chemotherapy, making dietary interventions easy to control and deliver.

The key research question is "Does dietary restriction of serine induce novel metabolic vulnerabilities in infant leukaemia and can this identify new less-toxic and more effective therapies". To answer this question you will first grow infant leukaemia cell lines in vitro and investigate the effects of serine starvation on serine synthesis, cellular growth, survival, gene expression, oxidative stress and energy production. You will then take a hypothesis-driven approach by combining serine starvation with inhibition of the key compensatory pathways activated in the presence of serine starvation. This will be complemented by novel discovery science using a 2893-compound high-throughput metabolism targeting library - available in our laboratory - which will identify novel drug targets in an unbiased fashion.

Following ranking of the most promising drug targets and confirmation of mechanisms of action in vitro, you will then be able to investigate the effects of the new therapy in vivo. The Ottersbach laboratory has developed a mouse model that recapitulates the clinical and biological features of infant leukaemia (ref 2). Using this model the effect of the drug on leukaemia growth will be compared between mice fed a normal diet and a serine-depleted diet. At the end of the experiment leukaemia cells will be harvested and analysed ex vivo to compare effects seen in vitro with the more complex in vivo environment. In this way you will identify promising new diet/drug combinations suitable for moving towards clinical use.

This project will provide you with training and experience in a wide variety of experimental techniques in the fields of cancer metabolism, therapeutic target identification and animal modelling. The CRUK Scotland Cancer Centre has a world-class reputation in these areas, and you will have access to all the necessary support and facilities to undertake this exciting PhD.

Application Procedure

Up to 3 studentships are available to start in September 2022 for outstanding applicants with a stipend of £19,000 p/a. These are funded by the CRUK Scotland Centre, a joint initiative between Edinburgh and Glasgow. Successful students will be registered for their degree in either Glasgow or Edinburgh, depending on the project they apply for.

We are looking for students with a very good degree in a Life Sciences subject and an aptitude for experimental work, who are also highly committed to pursuing a PhD and a career in cancer research. You should hold at least an upper second-class degree in a relevant subject and comply with English language requirements.

All applications will be administered centrally via the University of Edinburgh, please apply on the link below - this includes Glasgow-based projects with Glasgow-based supervisors: https://www.star.euclid.ed.ac.uk/public/urd/sits.urd/run/siw_ipp_lgn.login?process=siw_ipp_app&code1=PRPHDCECRC1F&code2=0020

Closing date: 27 May 2022

Interviews are expected to be held week beginning 27 June.

Applications are open to all individuals irrespective of nationality or country of residence.



Research Mahnoor 290x200

Read more about the Research Groups working at the Beatson Institute.



Seminars 2021

Find out more about our seminars including our Distinguished Seminar Programme.